Navigation Links
New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications

WARRINGTON, Pa., Oct. 18, 2011 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today reported that, in a recently published study in the Journal of Neonatal-Perinatal Medicine, nearly all neonatologists (92 percent) interviewed stated they were concerned about the exposure of newborn children to animal-derived medications. Additionally, two-thirds of parents with children in the neonatal intensive care unit (NICU) who were interviewed in the same study wanted to be informed if an animal-derived medication were administered to their newborn child.  More than half of parents expressed a preference for humanized or synthetic products of comparable efficacy over an animal-derived medication. In addition, 58 percent of parents stated their primary objection to use of animal-derived medications was based on potential safety concerns, while 27 percent stated their objection was based on social and religious considerations.  The study highlights the growing need for synthetic medication options that can address persisting concerns around the use of animal-derived medications in newborn children.

"The concerns shared by neonatologists and parents of children in the NICU are not unfounded and underscore the need for the pharmaceutical industry to pursue safe and effective alternatives to animal-derived drugs," said Dr. Steven Donn, study co-author and Professor of Pediatrics, University of Michigan Health System. "Concerns about use of animal-derived medications exist and there is a need for further education for neonatal healthcare practitioners regarding the origin and choice of available medications."

The study also revealed that, today, 97 percent of neonatologists seldom, if ever, discuss the source of medications or their concerns about administering animal-derived medications.  However, if an alternative synthetic agent is considered to have comparable safety and efficacy, 78 percent of neonatologists believe parents should be informed of the treatment alternative for their newborn.

Animal-derived medications are routinely used in the NICU today.  Respiratory Distress Syndrome (RDS) is a prevalent problem among premature infants for which animal-derived surfactants are frequently administered.  Currently, there is no comparable synthetic agent available to address RDS.  SURFAXIN®, Discovery Labs' lead product candidate, is a synthetic therapeutic surfactant.  SURFAXIN is currently under review for potential marketing approval by the U.S. Food and Drug Administration (FDA) for the prevention of RDS in premature infants with a target action date of March 6, 2012 under the Prescription Drug User Fee Act (PDUFA).

About the Study

The study was conducted by two leading academic physicians at the University of Michigan. The purpose of the study was to explore and compare parents' and neonatologists' views regarding animal-derived versus synthetic medications. Questionnaires were distributed to the Directors of US Neonatology Divisions and to parents of the newborns admitted to a tertiary level neonatal intensive care unit (NICU).  Of the 98 neonatologists and 150 parents contacted, 66 (67 percent) neonatologists and all parents responded. (Study Reference: Do neonatologists and parents share the same concerns about animal-derived pharmaceutical agents? Sarkar and Donn, Journal of Neonatal-Perinatal Medicine, 2011)

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for patients with respiratory disease and improve the standard of care for pulmonary medicine.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosol formulations. Discovery Labs is also developing its proprietary drug delivery technologies – capillary aerosol generator and novel patient interface adapters – to enable efficient, targeted upper respiratory or alveolar delivery of aerosolized KL4 surfactant.  Discovery Labs believes that its proprietary technology makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties, including those related to the Company's comprehensive preclinical program, development and manufacturing activities and related regulatory efforts, are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

SOURCE Discovery Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
2. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
3. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
4. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
5. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
6. Study Shows That Roches Investigational Drug for Alzheimers Disease Removes Amyloid Plaques From the Brain
7. Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
8. Hologic Announces Six-year Follow-up Results from the MammoSite Targeted Breast Irradiation Registry Study
9. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
10. FDA CONSUMER HEALTH INFORMATION -- Foreign Exporters Study Food Safety Law
11. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):